CA2242851A1 - Methode de controle de l'assemblage des fibrilles de proteine - Google Patents

Methode de controle de l'assemblage des fibrilles de proteine Download PDF

Info

Publication number
CA2242851A1
CA2242851A1 CA 2242851 CA2242851A CA2242851A1 CA 2242851 A1 CA2242851 A1 CA 2242851A1 CA 2242851 CA2242851 CA 2242851 CA 2242851 A CA2242851 A CA 2242851A CA 2242851 A1 CA2242851 A1 CA 2242851A1
Authority
CA
Canada
Prior art keywords
peptide
fluorophore
donor
beta
denaturant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2242851
Other languages
English (en)
Inventor
Avi Chakrabartty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ontario Cancer Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2242851A1 publication Critical patent/CA2242851A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Méthode permettant de contrôler in vitro l'assemblage des fibrilles de peptide ou de protéine. Pour obtenir une sensibilité à des concentrations nanomolaires de l'ordre de celles observées in vivo, on recourt dans cette méthode à un transfert d'énergie de fluorescence entre des fluorophores donneur et receveur étroitement juxtaposés. Le procédé consiste à fixer un fluorophore donneur à un peptide ou une protéine fibrillogène, et fixer un fluorophore receveur à un deuxième peptide ou une deuxième protéine fibrillogène. Les fluorophores donneur et receveur sont situés sur les premier et second peptides ou protéines, et sont ainsi juxtaposés de façon à permettre le transfert d'énergie entre eux lors de la formation de fibrilles. Les peptides ou protéines contenant le fluorophore sont mélangés en solution à une concentration physiologique normale, et on suit la formation de fibrilles en observant le transfert d'énergie de fluorescence entre les fluorophores donneur et receveur. Le mélange est réalisé de préférence par l'apport en quantités équimolaires de peptides ou de protéines dans une solution dénaturante; on commence le contrôle de la formation de fibrilles en diluant le dénaturant.
CA 2242851 1995-08-17 1996-08-16 Methode de controle de l'assemblage des fibrilles de proteine Abandoned CA2242851A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51561595A 1995-08-17 1995-08-17
US08/515,615 1995-08-17

Publications (1)

Publication Number Publication Date
CA2242851A1 true CA2242851A1 (fr) 1997-02-27

Family

ID=24052074

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2242851 Abandoned CA2242851A1 (fr) 1995-08-17 1996-08-16 Methode de controle de l'assemblage des fibrilles de proteine

Country Status (3)

Country Link
AU (1) AU6728396A (fr)
CA (1) CA2242851A1 (fr)
WO (1) WO1997007402A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407132B1 (en) 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
FR2766927B1 (fr) * 1997-07-31 1999-11-05 Centre Nat Rech Scient Methodes et kits pour le diagnostic de la maladie d'alzheimer
CA2301142A1 (fr) 1997-08-14 1999-02-25 The Regents Of The University Of California Peptides amyloides a.beta. fluorescents et utilisation de ces derniers
US7105307B2 (en) 1997-08-30 2006-09-12 Cyclacel, Ltd. Compositions and methods for screening for modulators of enzymatic activity
US6329356B1 (en) 1998-04-10 2001-12-11 Neurochem, Inc. Phosphono-carboxylate compounds for treating amyloidosis
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US6399314B1 (en) 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
WO2002042321A2 (fr) * 2000-11-24 2002-05-30 Isis Innovation Limited Fibrilles melangees
EP1497321B1 (fr) 2002-04-19 2011-06-29 The Governing Council Of The University Of Toronto Methodes et compositions immunologiques pour le traitement de la maladie d'alzheimer
FR2871464B1 (fr) * 2004-06-15 2006-09-08 Centre Nat Rech Scient Cnrse Collections de composes tracables et leurs utilisations
US8044100B2 (en) 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
EP0552108B1 (fr) * 1992-01-17 1999-11-10 Lakowicz, Joseph R. Essai fluoro-immunologique impliquant un transfert d'énergie par phase-modulation

Also Published As

Publication number Publication date
AU6728396A (en) 1997-03-12
WO1997007402A1 (fr) 1997-02-27

Similar Documents

Publication Publication Date Title
Huang et al. Structural studies of soluble oligomers of the Alzheimer β-amyloid peptide
US9638702B2 (en) Detection of conformationally altered proteins
Soto et al. The conformation of Alzheimer's β peptide determines the rate of amyloid formation and its resistance to proteolysis
EP1242822B1 (fr) Procede de detection de proteines amyloidogeniques
US6462171B1 (en) Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
Maggie et al. Brain amyloid—a physicochemical perspective
EP2156181B1 (fr) Sondes peptidiques pour des diagnostics et des produits thérapeutiques
US6770448B2 (en) Fluorescent amyloid Aβ peptides and uses thereof
Huang et al. Fibrillogenesis of Alzheimer Aβ peptides studied by fluorescence energy transfer
EP2312313A2 (fr) Sondes immobilisées et methodes de détection de protéines prions modifiées de maniére conformationnelle
Fabian et al. Comparative analysis of human and Dutch-type Alzheimer β-amyloid peptides by infrared spectroscopy and circular dichroism
Sian et al. Oligomerization of β-amyloid of the Alzheimer’s and the Dutch-cerebral-haemorrhage types
CA2242851A1 (fr) Methode de controle de l'assemblage des fibrilles de proteine
JP2007536502A5 (fr)
Ratnaswamy et al. The amyloidogenicity of gelsolin is controlled by proteolysisand pH
Scheidt et al. Conformation of Pyroglutamated Amyloid β (3–40) and (11–40) Fibrils–Extended or Hairpin?
Hu Engineering of beta-amyloid variants to create molecular probes and modulators for aggregation of beta-amyloid
Porat Aggregation of Amylin in type II diabetes: Molecular recognition elements in islet amyloid assembly and functional inhibition
Nagami et al. Different Roles of Metal Ions Both in the Formation of Amyloid-β Fibri and Superoxide

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead